High dose famotidine in ranitidine resistant severe oesophagitis: a pilot study.
Fifty-three asymptomatic patients who, in spite of continuous treatment with ranitidine 300 mg bid for six months, had active severe oesophagitis, Savary and Miller grade III-IV or Barretts ulceration at endoscopy were treated with high dose famotidine. In the severe oesophagitis group famotidine 40 mg bid, 13/29 (44%) healed at eight weeks and 17/29 (58%) at sixteen weeks. In the Barrett's ulcer group famotidine 40 mg tid, 10/24 (41%) healed at eight weeks and 18/24 (75%) at sixteen weeks. Famotidine in high doses was well tolerated in this age group (mean 66.75 years), with 5/53 (9%) minor adverse events recorded. Famotidine in high dose is effective in the treatment of ranitidine resistant severe oesophagitis or Barrett's ulceration.
Edge
D P
DP
Palmerston North Hospital.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D015738:Famotidine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011899:Ranitidine / Q000627:therapeutic use
D015738:Famotidine; D011899:Ranitidine